Helical tomotherapy lowers lattice valley doses versus VMAT at the cost of longer delivery

In 22 paired lattice plans, helical tomotherapy reduced valley-to-peak dose ratios and low-dose spill versus VMAT but required 2.5-fold longer beam-on time.

KEY POINTS

  • This retrospective dosimetric analysis conducted within the STRYKE trial framework compared helical tomotherapy (HT-LRT) with VMAT-based lattice radiotherapy (VMAT-LRT) in 22 patients with bulky tumors previously treated between 2019 and 2025. The cohort included soft tissue sarcomas, thoracic malignancies, gynecological tumors, and melanoma, with a median GTV of 751.9 cm³ (range 380.2–4,927.7 cm³) in the main Results section. Half the patients had originally received neoadjuvant treatment and half non-neoadjuvant or palliative treatment; the present analysis involved retrospective replanning rather than clinical delivery of lattice RT.
  • Both modalities were planned using the same prescription of 21 Gy in three fractions and a staggered triangular lattice arrangement, with 1-cm-diameter spherical vertices spaced approximately 5 cm apart. Vertices were positioned within a GTV contracted by 2 cm, with a median of five vertices per case (range 2–21). Helical plans used the Accuray Radixact platform, while VMAT plans employed four arcs across two isocenters; the two techniques were optimized using different treatment planning systems.
  • Helical tomotherapy consistently produced lower valley-to-peak dose ratios (VPDR), indicating stronger spatial dose modulation. Across the 22 paired plans, median VPDRWu was 0.29 with HT-LRT versus 0.37 with VMAT-LRT, while the DVH-based VPDRD90/D10 was 0.31 versus 0.42, and pairwise median VPDR was 0.46 versus 0.54 (all p<0.001). The advantage was observed across anatomical subgroups and was particularly pronounced for deep-seated abdominal tumors.
  • The degree of benefit depended on the direction of dose sampling. In the transverse radial direction, VPDR decreased from 0.59 with VMAT to 0.43 with helical tomotherapy (p<0.001), while superior-inferior VPDR decreased from 0.53 to 0.47 (p<0.001). In contrast, no significant differences were found along coronal diagonal (0.48 vs 0.49; p=0.321) or sagittal diagonal (0.50 vs 0.49; p=0.625) trajectories. These findings demonstrate that scalar VPDR values can conceal substantial directional variation in lattice dose distributions.
  • Lower valley doses were achieved without significantly compromising vertex D95%. Median vertex-target D95% was 20.23 Gy with HT-LRT versus 20.03 Gy with VMAT-LRT (p=0.116), while vertex V95% increased from 96.07% to 98.77% (p=0.032). In the intervertex compartment, median D95% decreased from 8.55 to 6.64 Gy and D50% from 10.61 to 7.28 Gy (both p<0.001). Mean GTV dose distribution was intentionally heterogeneous, and whole-tumor dose homogeneity was not the planning objective.
  • Helical tomotherapy reduced selected normal-tissue low-dose metrics but required substantially more delivery time. External-to-PTV V5Gy decreased from 5.10% with VMAT to 2.29% with HT-LRT (p=0.008), and near-maximum external dose decreased from 7.62 to 6.03 Gy (p=0.001). However, median beam-on time increased from 389 to 961.5 seconds per fraction (p<0.001), approximately a 2.5-fold increase, while monitor units increased from 1,969.9 to 13,813.8 per fraction, nearly sevenfold.
  • Clinical effectiveness and delivery robustness were not evaluated. The plans used a relatively sparse lattice geometry, with vertices comprising only 0.1–0.3% of GTV, and some directional analyses included very few evaluable vertex pairs. Different optimization engines and planning strategies could have contributed to the observed differences, while longer helical treatment times may introduce additional intrafraction motion concerns. No clinical local control, symptom relief, toxicity, or immune-mediated response outcomes were compared.

CLINICAL TAKEAWAY

Helical tomotherapy may achieve stronger peak-to-valley dose separation and lower low-dose normal-tissue exposure than VMAT for selected bulky tumor lattice plans, particularly in radial and superior-inferior directions. However, substantially longer beam-on time, dependence on planning methodology, and the absence of clinical outcome data prevent conclusions that helical delivery is the superior clinical lattice radiotherapy platform.

SOURCE

Frontiers in Oncology

Browse more research Suggest a correction